Melanoma and Advanced Melanoma
Clinical research is centred on melanoma, including metastatic melanoma and advanced melanoma, with a strong focus on immune-based treatment approaches and disease control in patients with limited options.
- Metastatic melanoma
- Anti-PD1–refractory melanoma
- Immune checkpoint inhibitor combinations
Interest extends to patients whose disease has progressed after prior immunotherapy, reflecting a therapeutic emphasis on checkpoint blockade combinations in difficult-to-treat cutaneous malignancies.
Cutaneous Squamous Cell Carcinoma
Another major area of activity is cutaneous squamous cell carcinoma, particularly locally advanced and metastatic disease, where the sponsor investigates immune-oncology strategies aimed at improving tumour response.
- Locally advanced CSCC
- Metastatic CSCC
- Response assessment in skin cancer
This work reflects a focused interest in advanced skin cancer and the use of combination regimens to address tumours resistant to prior treatment.
Uveal Melanoma and Ocular Tumors
The sponsor also supports studies in metastatic uveal melanoma, a distinct melanoma subtype with specialised therapeutic needs and limited systemic treatment choices.
- Advanced uveal melanoma
- Systemic immunotherapy
- Immune-resistant ocular melanoma
These trials highlight interest in ocular oncology and in immunotherapy combinations for patients with advanced disease.
Hepatocellular Carcinoma and Other Solid Tumors
Research activity extends beyond skin cancer into hepatocellular carcinoma and broader solid tumors, including advanced and metastatic settings.
- Hepatocellular carcinoma
- Advanced solid tumors
- Metastatic solid tumours
Studies in these areas indicate a therapeutic focus on oncology platforms that can be applied across multiple tumour types, especially where immune-based treatment options are being explored.
